跳至主要内容
临床试验/NCT03559114
NCT03559114招募中3 期

PROTEST Trial - PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury, a Double-blind Randomized Controlled Trial

Sunnybrook Health Sciences Centre12 个研究点 分布在 1 个国家目标入组 1,100 人开始时间: 2018年7月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
1,100
试验地点
12
主要终点
Clinically important VTE

研究概览

简要总结

This is a pilot study, phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).

详细描述

Patients with severe brain injury are at risk for developing blood clots in their legs, which can travel to the lungs. This potentially serious complication is known as venous thromboembolism (VTE). Anticoagulants are commonly used to prevent VTE in hospital patients. However, in patients with major head injury, anticoagulant prevention is commonly delayed for the fear that it can potentially lead to further bleeding in the brain. Another method that aims to prevent blood clots involves the use of sequential compression device (SCD) that compress the legs and increase the flow of blood in the leg veins.

This study will compare results from patients who receive the SCDs only to those who receive both SCD and anticoagulants. The outcome of this study will provide information about how best to prevent blood clots while not increase brain bleeding after head injury.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Anticoagulant

Active Comparator

Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.

干预措施: Dalteparin (Drug)

Saline

Placebo Comparator

Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.

干预措施: Saline (Drug)

结局指标

主要结局

Clinically important VTE

时间窗: 8 days

Composite outcome of clinically-important VTE within 7±1 days after randomization defined as any of: 1. Symptomatic, objectively-confirmed pulmonary embolism (PE), or 2. Symptomatic, objectively-confirmed, proximal leg deep vein thrombosis (DVT), or 3. Proximal (above knee) leg DVT on compression ultrasonography on Day 7±1

次要结局

  • 180-day Mortality(180 days)
  • Functional neurological outcome at day 30 as measured by Glasgow Outcome Scale Extended(30 days)
  • Clinically-important ICB (Intracranial bleeding) progression(7 days)
  • Objectively confirmed new or progressing ICB on radiology,(8 days)
  • Functional neurological outcome at day 180 as measured by Glasgow Outcome Scale Extended(180 days)
  • Quality of life outcome at 180 days as measured by the EuroQol5D(180 days)
  • 7-day Mortality(7 days)
  • Quality of life outcome at 30 days as measured by the EuroQol5D(30 days)
  • 30-day Mortality(30 days)
  • Delayed VTE after day 7(30 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验